Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 314
Selected: 0
NCT IDTitle
NCT04757259Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
NCT04551586A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
NCT02293382A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
NCT03578146Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT06830798Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT01765855An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects
NCT05288829A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT02013037The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
NCT05778071Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05319899A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT03759366A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
NCT01755429To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
NCT00040157Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
NCT05396742Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
NCT06071442Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
NCT02987504Study of Samalizumab in Patients With Advanced Cancer
NCT00838513Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
NCT01303952Therapy of Chronic Cold Agglutinin Disease With Eculizumab
NCT04170023Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
NCT01194973An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT04730804A Study of ALXN1830 in Healthy Adult Participants
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT04952545Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
NCT01849562Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
NCT02496689Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
NCT03748823Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
NCT01106027Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
NCT04201262An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT01919346Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
NCT01275287Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
NCT01758432Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT06449001Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT04233073Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
NCT04422431Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT07732361A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).
NCT02596100A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations
NCT05239221AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
NCT04195763Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)